Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.
Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.
Xeris Biopharma (Nasdaq:XERS) announced a U.S. Patent and Trademark Office Notice of Allowance for U.S. Patent Application No. 17/151,405 covering the use of KEVEYIS (dichlorphenamide).
The patent is expected to protect KEVEYIS in the U.S. through 2039, with Orange Book listing planned after issuance.
Xeris Biopharma (Nasdaq:XERS) entered privately negotiated exchange agreements to retire approximately $23 million of its 8.00% Convertible Senior Notes due 2028. This is expected to reduce annual interest expense by about $2 million.
Consideration totals about $23 million in cash plus common stock based on a 21‑day VWAP starting June 11, 2026. Assuming a $6.71 share price, Xeris expects to issue roughly 4.6 million shares. After closing, $10.5 million principal of the Notes will remain outstanding.
Xeris (NASDAQ: XERS) reported strong Q1 2026 results: total product revenue rose 43% to $82.45 million and Recorlev net revenue nearly doubled to $49.8 million (≈95% growth). Total revenue was $83.13 million. Gross margin improved to 87%. Net income was $2.2 million; Adjusted EBITDA was $15.1 million. Management tightened 2026 total revenue guidance to $380–$390 million and highlighted planned Phase 3 initiation for XP-8121 later in 2026. Shares outstanding were 172,642,055 at April 30, 2026.
Xeris Biopharma (Nasdaq: XERS) will report first quarter 2026 financial results before U.S. market open on May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. ET the same day. Attendees are advised to pre-register and can access the webcast, replay, and event materials on the company's investor relations website.
Xeris (Nasdaq: XERS) announced that on April 1, 2026 its Compensation Committee granted 304,975 restricted stock units to 90 new employees under the company's Inducement Equity Plan pursuant to Nasdaq Rule 5635(c)(4).
The RSUs vest in equal annual installments over three years and are subject to continued employment and the plan's award terms.
Xeris (Nasdaq: XERS) reported record Q4 revenue of $85.8M and full‑year 2025 revenue of $291.8M, driven by Recorlev, Gvoke and Keveyis growth. The company gave 2026 guidance of $375M–$390M, expects higher R&D and SG&A spend to support XP‑8121 Phase 3 and Recorlev expansion, and reported Adjusted EBITDA improvement.
Summary not available.
Xeris Biopharma (Nasdaq: XERS) will release its fourth quarter and full year 2025 financial results before U.S. market open on March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. ET that day to discuss results and guidance.
Investors can pre-register for the call and join the live webcast via the company’s investor events links; a replay will be available on the investor relations site after the call.
Xeris (Nasdaq: XERS) announced unaudited preliminary results for FY2025 and Q4, expecting $292 million in total 2025 revenue, above prior guidance of $285–$290 million and representing 44% growth year-over-year. The company expects Recorlev net revenue of $45 million in Q4 and $139 million for full-year 2025. Recorlev ended the year with ~700 patients on therapy. Gvoke revenue grew >13% versus prior year and Keveyis patient numbers increased versus 2024. Xeris reported positive Adjusted EBITDA in every quarter, strengthened IP with a new Orange Book-listed U.S. patent for Recorlev and a composition-of-matter patent for XP-8121, and plans to release full FY2025 results and 2026 outlook on March 2, 2026.
Xeris Pharmaceuticals (Nasdaq: XERS) announced that on January 2, 2026 its Compensation Committee granted 181,550 restricted stock units to 50 new employees under the company's Inducement Equity Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest in equal annual installments over three years and are subject to continued employment and the plan's award agreement terms.